z-logo
Premium
Preparation and evaluation of chitosan/β‐cyclodextrin magnetic nanoparticles as a photodegradable and hydrophobic drug delivery carrier
Author(s) -
Shi Xu,
Xiang Cuncheng,
Liu Yuehua,
Lin Huihuan,
Xu Yi,
Ji Jingou
Publication year - 2017
Publication title -
journal of applied polymer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.575
H-Index - 166
eISSN - 1097-4628
pISSN - 0021-8995
DOI - 10.1002/app.45076
Subject(s) - nanocarriers , superparamagnetism , zeta potential , nanoparticle , cyclodextrin , magnetic nanoparticles , chitosan , bioavailability , chemical engineering , drug delivery , drug carrier , materials science , chemistry , nanocapsules , nuclear chemistry , nanotechnology , organic chemistry , magnetization , bioinformatics , physics , quantum mechanics , magnetic field , engineering , biology
In this study, novel tumor targeting nanocarriers comprised of chitosan (CS)/β‐cyclodextrin (β‐CD) magnetic nanoparticles were prepared to improve the photodegradable stability and bioavailability of hydrophobic drug. Resveratrol (Res) with photodegradable and hydrophobic properties was selected as a model drug. The photodegradation rate of Res in Fe 3 O 4 nanoparticles solution was 7.8 times lower than that in the ethanol solution . In addition, the value of the saturation magnetization of CS/β‐CD nanoparticles was found to be 19.56 emu/g with characteristic of superparamagnetism. Approximately 90% Res was entrapped into the CS/β‐CD magnetic nanoparticles with the size distribution ranging from 200 to 359 nm, and the nanoparticles were spherical in shape with high zeta potentials. Furthermore, the formation of CS/β‐CD nanoparticles showed a sustained release in vitro . These results indicated that the obtained CS/β‐CD magnetic nanoparticles were a promising magnetic targeting carrier for photodegradable and hydrophobic drugs. © 2017 Wiley Periodicals, Inc. J. Appl. Polym. Sci. 2017 , 134 , 45076.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here